Alembic Pharmaceuticals Ltd Q3FY25; 23% fall in Profits

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Financial Results:

Alembic Pharmaceuticals Ltd reported Revenues for Q3FY25 of ₹1,693.00 Crores up from ₹1,631.00 Crore year on year, a rise of 3.8%.

Total Expenses for Q3FY25 of ₹1,525.00 Crores up from ₹1,448.00 Crores year on year, a rise of 5.32%.

Consolidated Net Profit of ₹138.00 Crores down 23.33% from ₹180.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹7.04, down 23.31% from ₹9.18 in the same quarter of the previous year.